Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.
Also called NCT03130426
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 161 participants
- Registry
-
NCT03130426
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT03130426. Randomized; no masking; primary purpose treatment. Start 2017-06-27 (actual); primary completion 2019-06-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
- Acronym
- REMIT-iGL
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- iGlarLixi
- Intervention (Drug)
- Insulin Glargine
- Intervention (Drug)
- Metformin
- Intervention (Behavioral)
- Lifestyle therapy
- Lead sponsor
- Population Health Research Institute
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct03130426- Content hash
10bdf55ad848bc4223478d0025612978c28fe3c6da6ecb4aa9a04ca41fabed47